Bench 2 Breakthrough Podcast Episode 4 - Regenerative Medicine, Innovation and Commercialisation

Bench2Breakthrough Podcast – Regenerative Medicine, Innovation and Commercialisation

🎙Episode 4 of Accelagen’s Bench2Breakthrough Podcast, host Greg Plunkett sits down with Silvio Tiziani, CEO of the Centre for Commercialisation of Regenerative Medicine (CCRM Australia), to explore the rapidly evolving world of regenerative medicine and advanced therapies.

Together, they discuss how Australia can translate world-class scientific research into commercial success, the growing impact of cell and gene therapies, and the critical role of manufacturing, workforce development, investment, and ecosystem collaboration in bringing life-changing treatments to patients.

The conversation also examines Australia’s competitive position in the global biotechnology landscape, emerging opportunities in regenerative medicine, and the steps needed to accelerate innovation from laboratory discovery to clinical and commercial reality.

Key topics covered:

• Australia’s evolving biotechnology and regenerative medicine ecosystem
• Cell and gene therapy innovation and commercialisation pathways
• Manufacturing and workforce challenges in advanced therapies
• The role of government and private investment in building industry capability
• Australia’s global competitiveness in clinical research and innovation
• Future trends shaping regenerative medicine over the next five years

📰 In the wrap of recent news, we discuss the key changes as proposed in the Australian Governments May 2026 Federal Budget announcements and what this may mean for the industry locally.

🎧 Click here to listen to the episode!

‍We love your feedback and if you have any questions from this episode, let us know and we will cover in future episode.